A message from Altum Sequencing

Altum Sequencing is positioning its liquid biopsy, ultra-sensitive NGS, and AI platform as a scalable way to improve cancer treatment monitoring, detect relapse earlier, and identify emerging resistance. For CIOs and technology leaders in healthcare and life sciences, the strategic signal is that longitudinal molecular data platforms are moving from research into clinical and commercial workflows, increasing demand for interoperable data infrastructure, analytics, and AI-enabled decision support across hospitals, pharma, and clinical research organizations.